Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | DDO | Q99489 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31192183 | 1.00 | ALDH1A1 (0.68) | ALDH1A1KDM4ERAB9ADAODDO | |
| SCHEMBL9273029 | 0.83 | KDM4E (0.58) | ALDH1A1KDM4ERAB9AHPGDHSD17B10 | |
| SCHEMBL12559597 | 0.81 | RAB9A (0.76) | ALDH1A1KDM4ERAB9ADAODDO | |
| SCHEMBL5313245 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4ERAB9AHPGDHSD17B10 | |
| SCHEMBL14485203 | 0.79 | KDM4E (0.65) | ALDH1A1KDM4ERAB9ADAODDO | |
| SCHEMBL31146266 | 0.79 | KDM4E (0.65) | ALDH1A1KDM4ERAB9ADAODDO | |
| SCHEMBL7654131 | 0.76 | RAB9A (0.72) | ALDH1A1KDM4ERAB9ADAODDO | |
| SCHEMBL6920607 | 0.76 | MAPT (0.61) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| SCHEMBL28543275 | 0.76 | AHR (0.52) | ALDH1A1KDM4ERAB9ADAODDO | |
| SCHEMBL27410859 | 0.76 | ALDH1A1 (0.61) | ALDH1A1KDM4ERAB9AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-1912647-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-11 | — | — | EP | disclosed |
| EP-2408863-A2 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | Promega Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8017606-B2 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017606-B2 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | JANSSEN-CILAG (FR) | 2011-05-26 | — | — | US | disclosed |
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | JANSSEN-CILAG (FR) | 2011-05-26 | — | — | US | disclosed |
| US-7902225-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902225-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| WO-2010107816-A2 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | PROMEGA CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA N.V. | 2008-10-16 | — | — | US | disclosed |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA N.V. | 2008-10-16 | — | — | US | disclosed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | NQO2, NAT1, HRH1 | ALDH1A1 1105/4885KDM4E 4569/4885RAB9A 903/4885 |
| US-20070093478-A1 | Novel mycobacterial inhibitors | NQO2, NAT1, HRH1 | ALDH1A1 1106/4885KDM4E 4559/4885RAB9A 768/4885 |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | RER1, HRH4, HRH1 | ALDH1A1 2650/4885KDM4E 3332/4885RAB9A 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.